Last spring, Johnson & Johnson’s new type 2 diabetes drug Invokana, previously known as canagliflozen, became the first medication approved in the United States from a new class of drugs known as SGLT-2 inhibitors. While the honor of being the first treatment in a drug class has its benefits, it also has drawbacks. Novel drugs offer the promise of a new approach to treating diseases and conditions, but they are also met with caution by doctors, many of whom prefer to take a wait-and-see approach, until more safety and efficacy data comes available. These drugs, like Invokana, are being pitted ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.